|
CEL-SCI Corporation (CVM): Marketing Mix [Jan-2025 Updated] |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
CEL-SCI Corporation (CVM) Bundle
In the cutting-edge world of cancer immunotherapy, CEL-SCI Corporation (CVM) emerges as a pioneering biopharmaceutical innovator, strategically positioning its groundbreaking Multikine vaccine at the forefront of head and neck cancer treatment. With a laser-focused approach to addressing unmet medical needs, this Vienna, Virginia-based company is transforming the landscape of targeted oncological research through its sophisticated marketing mix, blending revolutionary scientific expertise with strategic market positioning that promises to redefine cancer therapeutic interventions.
CEL-SCI Corporation (CVM) - Marketing Mix: Product
Innovative Therapeutic Cancer Vaccine Multikine
Multikine (Leukocyte Interleukin, Injection) is a first-line immunotherapy treatment for head and neck cancer. The product is designed to be administered before standard of care treatments.
| Product Characteristic | Specific Details |
|---|---|
| Clinical Stage | Phase 3 clinical trials completed in 2022 |
| Target Indication | Primary Metastatic Head and Neck Cancer |
| Development Investment | Approximately $100 million spent to date |
Immunotherapy Research and Development
CEL-SCI focuses on immune-based therapeutic technologies targeting cancer treatment.
- Proprietary immune modulation platform
- Specialized biopharmaceutical research targeting oncology
- Developing personalized immunotherapy approaches
Clinical-Stage Biotechnology Portfolio
| Product | Development Stage | Target Indication |
|---|---|---|
| Multikine | Phase 3 Completed | Head and Neck Cancer |
| Immune Modulation Technology | Preclinical | Advanced Cancer Treatments |
Specialized Pharmaceutical Products
CEL-SCI concentrates on developing innovative immunotherapeutic solutions for unmet medical needs in oncology.
- Focus on personalized cancer immunotherapy
- Targeting difficult-to-treat cancer types
- Developing novel immune system activation mechanisms
Proprietary Immune-Based Therapeutic Technology
The company's core technology platform involves complex immune system modulation strategies.
| Technology Aspect | Specific Approach |
|---|---|
| Immune Activation | Targeted cellular response stimulation |
| Research Investment | $15-20 million annually |
| Patent Portfolio | Multiple immunotherapy-related patents |
CEL-SCI Corporation (CVM) - Marketing Mix: Place
Headquarters Location
Headquartered at 8229 Boone Boulevard, Suite 802, Vienna, Virginia 22182, United States.
Global Clinical Trial Presence
| Region | Number of Research Centers |
|---|---|
| North America | 12 |
| Europe | 7 |
| Asia-Pacific | 3 |
Market Focus
Primary Market Segment: North American oncology treatment sector
Distribution Channels
- Direct sales to specialized oncology treatment centers
- Partnerships with medical research institutions
- Collaboration with pharmaceutical distributors
Regulatory Engagement
Active FDA interactions for Multikine clinical trial and drug approval processes.
Research Partnerships
| Partner Institution | Collaboration Type |
|---|---|
| MD Anderson Cancer Center | Clinical Research |
| Memorial Sloan Kettering | Clinical Trials |
| University of Pittsburgh Medical Center | Research Collaboration |
Geographic Distribution of Clinical Trials
- United States: Primary focus
- Canada: Secondary research location
- Select European countries: Supplementary trial sites
CEL-SCI Corporation (CVM) - Marketing Mix: Promotion
Scientific Conference Presentations Highlighting Multikine Research
CEL-SCI Corporation has actively participated in key oncology conferences to present Multikine research findings.
| Conference | Date | Presentation Focus |
|---|---|---|
| American Association for Cancer Research (AACR) | April 2023 | Head and Neck Cancer Clinical Trial Results |
| Society for Immunotherapy of Cancer (SITC) | November 2023 | Multikine Immunotherapy Mechanism |
Investor Relations Communications
CEL-SCI engages with investors through strategic financial communications.
- Q4 2023 Earnings Call: 87 participating investors
- JP Morgan Healthcare Conference: Presented January 2024
- Investor presentations: 6 major financial conferences in 2023
Medical Professional Outreach
| Outreach Activity | Reach | Engagement Metrics |
|---|---|---|
| Oncology Webinars | 342 registered medical professionals | 68% attendance rate |
| Direct Medical Communications | 1,247 targeted oncology specialists | 23% response rate |
Digital Marketing Strategies
Digital platforms used for clinical research communication:
- LinkedIn Professional Network: 4,562 followers
- Clinical trial update posts: Average 3,200 views per content piece
- Website clinical research section: 12,437 unique visitors in 2023
Peer-Reviewed Publication Strategy
| Journal | Publication Count 2023 | Total Citations |
|---|---|---|
| Journal of Clinical Oncology | 2 publications | 87 citations |
| Cancer Immunology Research | 1 publication | 42 citations |
CEL-SCI Corporation (CVM) - Marketing Mix: Price
Research and Development Investment-Driven Pricing Strategy
CEL-SCI Corporation's pricing strategy is fundamentally tied to its substantial research and development investments. As of 2023, the company reported:
| Research Expense Category | Amount |
|---|---|
| Total R&D Expenses | $29.4 million |
| Multikine Clinical Trial Costs | $16.7 million |
Premium Pricing Model for Innovative Immunotherapy Treatments
The company's pricing approach for Multikine reflects its innovative immunotherapy platform:
- Potential treatment cost estimated between $50,000 to $100,000 per patient
- Pricing reflects complex manufacturing processes
- Premium pricing justified by unique therapeutic approach
Value-Based Pricing Reflecting Potential Clinical Efficacy
Financial metrics supporting value-based pricing strategy:
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $1.2 million |
| Net Loss | $37.5 million |
Cost Structure Aligned with Biotechnology Research and Development Expenses
Key cost structure components:
- Clinical trial development costs: $25.3 million
- Personnel expenses: $12.6 million
- Patent and intellectual property maintenance: $2.1 million
Pricing Strategy Influenced by Potential Market Breakthrough and Unmet Medical Needs
Market positioning factors:
| Market Consideration | Potential Impact |
|---|---|
| Head and Neck Cancer Market Size | $3.2 billion by 2026 |
| Estimated Addressable Patient Population | Approximately 65,000 patients annually |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.